Spruce Biosciences Raises $88 Million in Series B Financing, co-led by Omega Funds and Abingworth
Amount Raised
$88 Million
Round Type
Series B
South San FranciscoBiotechnologyDescription
Spruce Biosciences today announced it has raised $88 million in Series B financing co-led by Omega Funds and Abingworth and supported by existing investors Novo Holdings and RiverVest Venture Partners, as well as new investors HealthCap Partners, Rock Springs Capital, Surveyor Capital (a Citadel company), Aisling Capital and Sands Capital. Spruce is a clinical stage biopharmaceutical company developing therapeutics for rare endocrine diseases. The proceeds will be used to further fund the clinical development of the company’s lead product, tildacerfont, in classic congenital adrenal hyperplasia (CAH) and other conditions.
Quick answer
Spruce Biosciences raised $88 Million in a Series B round, dated February 20, 2020. Spruce Biosciences is based in South San Francisco, California, United States.
- How much did Spruce Biosciences raise?
- Spruce Biosciences raised $88 Million in a Series B round on February 20, 2020.
- What does Spruce Biosciences do?
- Spruce Biosciences, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders.
- Where is Spruce Biosciences based and how big is it?
- Spruce Biosciences is based in South San Francisco, California, United States. Fundz records about 20 employees.
- Who are the decision-makers at Spruce Biosciences?
- Fundz holds 2 contacts at Spruce Biosciences, including the Founder. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Biotechnology around the same time
Companies in the same sectors as Spruce Biosciences that raised within 45 days of this round, from Fundz verified event records.
- Koneksa Health raised $9.6M on April 3, 2020.
- Rhythmic Health, Inc. raised $4.5M (Seed) on April 3, 2020.
- Vaxcyte, Inc. raised $110M on April 3, 2020.
- ViaCyte Inc. raised $33M on April 2, 2020.
- Diasome Pharmaceuticals raised $2.9M (Seed) on April 1, 2020.
- Galvanize Therapeutics raised $6.1M on April 1, 2020.
Who to call at Spruce Biosciences, and when
A new round usually means Spruce Biosciences is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Spruce Biosciences raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Spruce Biosciences, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Spruce Biosciences. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Spruce Biosciences raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansSpruce Biosciences raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.